OpenAlex 4,728 works 245 author topics
Works
4,728 works
-
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
CONTEXT: Gene expression analysis has identified several breast cancer subtypes, including basal-like, human epidermal growth factor receptor-2 positive/estrogen receptor negative (HER2+/ER-), luminal A, and luminal B. OBJECTIVES: To determine population-based distributions and clinical associations for breast cancer…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
BACKGROUND: Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early tripl…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
BACKGROUND: Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early tripl…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 99.9%
BACKGROUND: Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)-targeted therapy have a worse prognosis than those who have no residual cancer. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate of trastuzumab and the cy…
-
OpenAlex top 1%
OpenAlex 100.0%
PURPOSE: Expression profiling studies classified breast carcinomas into estrogen receptor (ER)+/luminal, normal breast-like, HER2 overexpressing, and basal-like groups, with the latter two associated with poor outcomes. Currently, there exist clinical assays that identify ER+/luminal and HER2-overexpressing tumors, an…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 99.9%
No abstract yet.
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 99.9%
No abstract yet.
-
OpenAlex top 1%
OpenAlex 99.6%
No abstract yet.
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
BACKGROUND: The addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery in an earlier analysis of th…
-
YÖKSİS
OpenAlex top 1%
OpenAlex 99.4%
Breast cancer is a heterogeneous complex of diseases, a spectrum of many subtypes with distinct biological features that lead to differences in response patterns to various treatment modalities and clinical outcomes. Traditional classification systems regarding biological characteristics may have limitations for patie…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
BACKGROUND: In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score…
-
OpenAlex top 1%
OpenAlex 99.5%
No abstract yet.
Academicians
245 academicians
- GÜLDENİZ KARADENİZ ÇAKMAK 65 author topics
- ENVER ÖZKURT 47 author topics
- AYKUT SOYDER 39 author topics
- YEŞİM ERALP 39 author topics
- DENİZ ESİN TEKCAN ŞANLI 35 author topics
- HALİL KARA 29 author topics
- İRFAN ÇİÇİN 29 author topics
- MUSTAFA ERKİN ARIBAL 27 author topics
- ERHAN GÖKMEN 26 author topics
- GÜL ALÇO 25 author topics
- MAHMUT GÜMÜŞ 25 author topics
- ÇETİN ORDU 23 author topics